查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1465121

多重抗药性结核病治疗药物市场：按产品、给药方法和分销管道 - 全球预测 2024-2030

Multidrug-resistant Tuberculosis Therapeutics Market by Offering (Medication, Therapies), Mode of Administration (Injectable Medications, Oral Medications), Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年耐多药结核病治疗市场规模为2.81亿美元，2024年达3.1132亿美元，2030年达5.8862亿美元，预计复合年增长率为11.14%。

多重抗药性结核病（MDR-TB）治疗是指对抗至少对两种最有效的抗结核药物异烟肼和利福平产生抗药性的结核分枝桿菌所采用的治疗策略和药物。这些药物是标准结核病治疗的基石，对它们的抗药性使治疗过程显着复杂化，因此需要使用替代药物。多重抗药性结核病治疗通常需要较长的治疗期，通常延长至 24 个月。此外，与用于治疗药物敏感结核病的第一线药物相比，二线药物更昂贵、效果较差且副作用风险更高。结核病发生率的上升，特别是在发展中国家，与有效多重抗药性结核病治疗的需求不断增加直接相关。此外，世界各地政府和非政府组织不断增加的财政援助、宣传宣传活动和支持政策也为市场成长做出了重大贡献。然而，更有效的新药物价格上涨限制了低收入国家的获取，并直接影响市场成长。此外，具有广泛抗药性的结核分枝桿菌的演化是一个主要障碍，需要继续研究和开发。此外，药物开发和诊断技术的创新正在提高多重抗药性结核病治疗的有效性和可及性。

主要市场统计
基准年[2023] 2.81 亿美元
预测年份 [2024] 31132万美元
预测年份 [2030] 58862万美元
复合年增长率（%） 11.14%

持续进行研究工作，支持开发治疗耐多药结核病的创新治疗方法

多重抗药性结核病治疗包括多种抗生素，旨在治疗至少对最强大的结核病药物异烟肼和利福平具有抗药性的结核分枝桿菌菌株。贝达喹啉给药是多重抗药性结核病治疗的一个重要进步。贝达喹啉的作用是抑制结核分枝桿菌产生能量所需的一种酶，有效地将其饿死。德拉马尼透过抑制分枝桿菌酸（细菌细胞壁的重要组成部分）的合成来针对分枝桿菌（导致结核病的细菌）。这种抑製作用可以杀死细菌。levofloxacin和莫西沙星属于Fluoroquinolones药物，是频谱抗生素。levofloxacin和莫西沙星是频谱抗生素，属于Fluoroquinolones药物。levofloxacin和莫西沙星透过抑制 DNA 旋转酶和拓朴异构酶 IV 酶发挥作用，这些酶对于细菌 DNA 复製、转录、修復和重组非常重要，从而杀死细菌细胞。 Pretomanid 是治疗结核病的新疗法之一。 Pretomanid 通常用作包括贝达喹啉和Linezolid的三药组合方案(BPaL) 的一部分，特别是用于治疗广泛抗药性结核病。耐多药结核病的治疗不仅限于药物治疗，还包括支持性护理，以满足患者的综合健康需求。

分销管道：提供密切医疗监测的线下分销管道日益重要

医院药局是主要的线下管道之一。医院药房位于医院内或医院附近，直接向住院患者提供药物，在许多情况下也向门诊病人提供药物。医院药局在需要密切医疗管理的多方面疾病（例如耐多药结核病）中发挥着重要作用。透过提供立即获得处方药物的途径来简化治疗过程。医院药剂师在为患者提供建议和管理药物治疗方案、确保充分满足耐多药结核病治疗的复杂要求方面发挥着至关重要的作用。零售药局独立于医院运营，更方便民众使用。零售药局位于社区内，提供患者取得处方药物的便利地点。零售药局满足更广泛的医疗保健需求，包括配发耐多药结核病药物。随着数位技术的出现，线上药局时代已经到来，并且作为耐多药结核病治疗药物等的分销管道正在不断发展。该平台允许患者及其看护者透过网路订购药物，并将药物直接送到家中。这种分发型态对于居住在偏远地区或难以进入传统药房的患者尤其有利。网路药局还具有更私密、更便利的优势，有时可以获得更广泛的产品，并且可能有更优惠的价格。

区域洞察

美国和加拿大是美洲对抗多重抗药性结核病的领先国家。与亚太地区和欧洲、中东和非洲地区相比，这些国家的发病率相对较低，凸显了不同的挑战和消费者需求。在美国，重点是在大量研究资金和专利申请的支持下，整合先进的诊断技术和开发新型疗法，目标是将创新治疗方法推向市场。欧盟国家应对耐多药结核病的方法结合了先进的医疗基础设施、强有力的公共卫生政策和研究倡议。重点放在早期检测、个人化医疗以及将新药和新疗法纳入治疗方案中。消费者行为的特征是对医疗保健系统高度信任并愿意参与疫苗接种和预防措施。中东面临独特的挑战，包括报告品质参差不齐和医疗保健服务的可近性。人们正在大力加强医疗保健系统、提高诊断准确性并意识提升。中国、日本和印度是亚太地区多重抗药性结核病（MDR-TB）高发生率国家。该地区的发病率很高，导致对有效治疗药物的大量需求。这些国家的消费者需求是由对可及、负担得起和有效的治疗方案的迫切需求所驱动的。

FPNV定位矩阵

FPNV定位矩阵对于评估多重抗药性结核病药物市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对耐多药结核病治疗药物市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.多重抗药性结核病治疗市场的市场规模和预测是多少？

2.在多重抗药性结核病治疗药物市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.多重抗药性结核病治疗市场的技术趋势和法规结构是什么？

4.耐多药结核病治疗市场主要厂商的市场占有率是多少？

5.进入耐多药结核病药物市场的适当型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地结核病病率上升
      • 越来越重视早期检测和个人化医疗
      • 加强开发新药的研发活动
    • 抑制因素
      • 耐多药药物的高成本且报销选择有限
    • 机会
      • 政府机构加强结核病宣导活动
      • 诊断程序的技术进步
    • 任务
      • 治疗耐多药结核病的复杂性
  • 市场区隔分析
    • 我们提供的服务：正在进行的研究工作，以加速开发治疗耐多药结核病的创新治疗方法。
    • 分销管道：线下分销管道变得越来越重要，因为它们提供密切的医疗监测
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章 耐多药结核病治疗市场：透过提供

  • 药品
  • 治疗方法

第七章依管理方式分類的多重抗药性结核病治疗药物市场

  • 注射药物
  • 口腔医学

第八章耐多药结核病治疗市场：依分销管道划分

  • 离线
  • 在线的

第九章 美洲耐多药结核病治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太耐多药结核病治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲耐多药结核病药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 透过策略伙伴关係在全球扩大获得突破性抗药性结核病治疗的机会
    • 全球抗击多重抗药性结核病的突破：贝达喹啉专利豁免，以改善低收入和中等收入国家的可及性
    • Aztreonam-阿维巴坦的临床成功代表了对抗革兰氏阴性菌感染疾病的突破
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-7A22CB0E5A7D

[186 Pages Report] The Multidrug-resistant Tuberculosis Therapeutics Market size was estimated at USD 281.00 million in 2023 and expected to reach USD 311.32 million in 2024, at a CAGR 11.14% to reach USD 588.62 million by 2030.

Multidrug-resistant tuberculosis (MDR-TB) therapeutics refers to the treatment strategies and medications employed to combat tuberculosis (TB) strains that have developed resistance to at least the two most potent anti-tuberculosis drugs, isoniazid and rifampicin. These drugs are the cornerstone of standard tuberculosis treatment, and resistance to them complicates the treatment process significantly, necessitating the use of alternative medications. MDR-TB therapeutics typically involve a longer treatment duration, often lasting up to 24 months, and the use of second-line drugs, which can be more expensive, less effective, and carry a higher risk of side effects compared to the first-line drugs used for drug-sensitive TB. The rising incidences of tuberculosis, particularly in developing countries, directly correlate with heightened demand for effective MDR-TB treatments. Moreover, increased funding, awareness campaigns, and supportive policies from governments and non-government organizations worldwide have significantly contributed to market growth. However, the elevated cost of newer, more effective drugs limits access in low-income countries, directly impacting market growth. The evolution of extensively drug-resistant TB strains poses a substantial hurdle, necessitating continuous research and development efforts. Furthermore, innovations in drug development and diagnostic technologies have enhanced the efficacy and accessibility of MDR-TB treatments.

KEY MARKET STATISTICS
Base Year [2023] USD 281.00 million
Estimated Year [2024] USD 311.32 million
Forecast Year [2030] USD 588.62 million
CAGR (%) 11.14%

Offering: Ongoing research activities boosting the development of innovative therapies to treat multidrug-resistant tuberculosis

Medication for MDR-TB comprises various antibacterial drugs designed to treat TB strains resistant to at least isoniazid and rifampin, the two most potent tuberculosis drugs. Bedaquiline medication represents a significant advancement in the treatment of MDR-TB. Bedaquiline works by inhibiting an enzyme the TB bacteria require to generate energy, effectively starving and killing the bacteria. Delamanid targets the mycobacteria causing TB by inhibiting mycolic acid synthesis, a crucial component of the bacterial cell wall. This disruption leads to the death of the bacteria. Levofloxacin and Moxifloxacin drugs belong to a class called fluoroquinolones, which are broad-spectrum antibiotics. They have been found effective in treating TB strains that have become resistant to first-line anti-TB drugs. Levofloxacin and Moxifloxacin work by inhibiting the DNA gyrase and topoisomerase IV enzymes, which are crucial for replication, transcription, repair, and recombination of bacterial DNA, thereby leading to bacterial cell death. Pretomanid medication is one of the newer additions to the arsenal against TB. Pretomanid is typically used as part of a three-drug regimen (BPaL) that includes Bedaquiline and Linezolid, specifically for treating extensively drug-resistant TB. MDR-TB therapies extend beyond medication, incorporating supportive treatments that address the comprehensive health needs of patients.

Distribution Channel: Growing significance of offline distribution channel as it provide close medical supervision

Hospital pharmacies are one of the primary offline channels. These are located within or adjacent to a hospital, where they provide medications directly to the in-patients and, in many instances, to out-patients as well. For multifaceted diseases such as MDR-TB, which require close medical supervision, hospital pharmacies play a critical role. They ensure the immediate availability of prescribed therapeutics, streamlining the treatment process. Hospital pharmacists are pivotal in advising and managing the drug regimen for patients, ensuring that the intricate requirements of MDR-TB therapy are adequately met. Retail pharmacies operate independently of hospital settings and are more accessible to the general public. They are located within communities, serving as a convenient point for patients to access their prescribed medications. Retail pharmacies cater to a broader spectrum of healthcare needs, including the dispensation of MDR-TB drugs. The beginning of digital technology has ushered in the era of online pharmacies, a growing distribution channel for MDR-TB therapeutics, among others. This platform allows patients or their caregivers to order medications via the Internet, which are then delivered directly to their homes. This mode of distribution is particularly beneficial for patients residing in remote areas or those who have difficulty accessing traditional pharmacy outlets. Online pharmacies also offer the advantage of privacy, ease, and sometimes access to a wider range of products and potentially better pricing.

Regional Insights

The United States and Canada represent the Americas in the battle against MDR-TB. Though the incidence rates in these countries are relatively lower compared to the Asia Pacific and EMEA regions, they highlight a different set of challenges and consumer needs. In the United States, the focus is on the integration of advanced diagnostic techniques and the development of novel therapeutics backed by significant research funding and patent filings that aim to bring innovative treatments to the market. In the EU countries, the approach towards MDR-TB involves a combination of advanced healthcare infrastructure, robust public health policies, and research initiatives. The emphasis is on early detection, personalized medicine, and the integration of new drugs and regimens into treatment protocols. Consumer behavior is characterized by a high level of trust in the healthcare system and a willingness to participate in vaccination and preventive measures. The Middle East faces unique challenges, including variable reporting quality and access to healthcare services. Efforts are concentrated on strengthening healthcare systems, improving diagnostic accuracy, and increasing public awareness. China, Japan, and India are key countries in the Asia Pacific region significantly impacted by multidrug-resistant tuberculosis (MDR-TB). This region witnesses a high incidence rate, contributing to a considerable demand for effective therapeutics. Consumer needs in these countries are driven by the urgent necessity for accessible, affordable, and efficient treatment options.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Multidrug-resistant Tuberculosis Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Multidrug-resistant Tuberculosis Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Multidrug-resistant Tuberculosis Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abcam Limited, Daiichi Sankyo Co., Ltd., Endo International Plc, Johnson & Johnson Services Inc., Lupin Limited, Macleods Pharmaceuticals Ltd., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi SA, and Santen Pharmaceutical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Multidrug-resistant Tuberculosis Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Offering
    • Medication
      • Bedaquiline
      • Delamanid
      • Levofloxacin
      • Moxifloxacin
      • Pretomanid
    • Therapies
  • Mode of Administration
    • Injectable Medications
    • Oral Medications
  • Distribution Channel
    • Offline
      • Hospitals Pharmacies
      • Retail Pharmacies
    • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Multidrug-resistant Tuberculosis Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Multidrug-resistant Tuberculosis Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Multidrug-resistant Tuberculosis Therapeutics Market?

4. What is the market share of the leading vendors in the Multidrug-resistant Tuberculosis Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Multidrug-resistant Tuberculosis Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of tuberculosis across the globe
      • 5.1.1.2. Growing emphasis is on early detection and personalized medicine
      • 5.1.1.3. Increasing research & development activities for new drug development
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of MDR drugs coupled with the limited reimbursement options
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing initiative from government organization for tuberculosis awareness
      • 5.1.3.2. Technological advancement in the diagnostics procedures
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities associated with the treatment of multidrug-resistant tuberculosis
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Ongoing research activities boosting the development of innovative therapies to treat multidrug-resistant tuberculosis
    • 5.2.2. Distribution Channel: Growing significance of offline distribution channel as it provide close medical supervision
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Multidrug-resistant Tuberculosis Therapeutics Market, by Offering

  • 6.1. Introduction
  • 6.2. Medication
  • 6.3. Therapies

7. Multidrug-resistant Tuberculosis Therapeutics Market, by Mode of Administration

  • 7.1. Introduction
  • 7.2. Injectable Medications
  • 7.3. Oral Medications

8. Multidrug-resistant Tuberculosis Therapeutics Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Offline
  • 8.3. Online

9. Americas Multidrug-resistant Tuberculosis Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Multidrug-resistant Tuberculosis Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Multidrug-resistant Tuberculosis Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Expanding Global Access to Groundbreaking DR-TB Treatment Through Strategic Partnerships
    • 12.3.2. Breakthrough in Global Fight Against MDR TB: Bedaquiline Patents Waived to Enhance Access in Low- and Middle-Income Countries
    • 12.3.3. Breakthrough in Combating Gram-Negative Bacterial Infections with Aztreonam-Avibactam's Clinical Triumphs
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY BEDAQUILINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY BEDAQUILINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DELAMANID, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DELAMANID, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LEVOFLOXACIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LEVOFLOXACIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MOXIFLOXACIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MOXIFLOXACIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY PRETOMANID, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY PRETOMANID, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 69. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 70. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 75. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 76. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 77. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 78. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 85. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 86. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 87. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 88. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 89. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 90. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 95. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 96. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 97. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 98. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 99. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 100. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 120. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 122. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 124. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 129. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 130. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 131. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 132. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 133. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 134. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 139. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 140. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 141. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 142. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 143. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 144. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 149. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 150. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 151. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 152. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 153. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 154. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 159. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 160. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 161. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 162. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 163. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 164. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 169. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 170. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 171. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 172. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 173. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 174. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 180. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 182. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 184. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 189. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 190. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 191. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 192. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 193. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 194. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 195. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 196. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 200. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 202. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 204. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 206. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 209. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 210. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 211. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 212. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 213. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 214. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 215. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 216. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 219. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 220. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 221. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 222. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 223. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 224. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 225. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 226. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 229. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 230. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 231. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 232. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 233. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 234. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 235. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 236. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 251. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 252. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 253. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 254. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 255. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 256. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 257. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 258. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 261. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 262. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 263. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 264. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 265. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 266. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 267. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 268. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)

TABL